A bridging assay for detection and characterization of anti-drug antibodies to dostarlimab, a new anti-PD-1 therapeutic monoclonal antibody

• Egile Nagusiak: Marilyn Patterson (Egilea), Lee Anne Beausang (Egilea), Bonita Rup (Egilea), Ronald R. Bowsher (Egilea), Kim Krug (Egilea), Murad Melhem (Egilea), Sharon Lu (Egilea)
• Formatua: Liburua
• Argitaratua: SpringerOpen, 2021-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Dostarlimab (JEMPERLI) is a humanized anti-programmed death 1 (PD-1) immunoglobulin (Ig)G4-kappa monoclonal antibody that binds to the PD-1 receptor and competitively inhibits binding of its ligands, PD-L1 and PD-L2. Dostarlimab was recently approved in the USA and the European Union. Becau...